177 related articles for article (PubMed ID: 31325732)
1. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
2. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Bartlett NL; Niedzwiecki D; Johnson JL; Friedberg JW; Johnson KB; van Besien K; Zelenetz AD; Cheson BD; Canellos GP;
Ann Oncol; 2007 Jun; 18(6):1071-9. PubMed ID: 17426059
[TBL] [Abstract][Full Text] [Related]
4. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
[TBL] [Abstract][Full Text] [Related]
6. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Zhang YC; Wang JN; Ma SY; Cai J; Su N; Huang HQ; Li ZM; Xia ZJ; Huang H; Liu PP; Xia Y; Cai QQ
Br J Haematol; 2022 Jan; 196(1):127-135. PubMed ID: 34618912
[TBL] [Abstract][Full Text] [Related]
7. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.
Swoboda R; Giebel S; Knopińska-Posłuszny W; Chmielowska E; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Kulikowski W; Taszner M; Mendrek W; Najda J; Czerw T; Olszewska-Szopa M; Czyż A; Giza A; Spychałowicz W; Subocz E; Szwedyk P; Krzywon A; Wilk A; Zaucha JM
Ann Hematol; 2021 Jul; 100(7):1755-1767. PubMed ID: 33625572
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
Cole PD; Schwartz CL; Drachtman RA; de Alarcon PA; Chen L; Trippett TM
J Clin Oncol; 2009 Mar; 27(9):1456-61. PubMed ID: 19224841
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
17. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
[TBL] [Abstract][Full Text] [Related]
19. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
